Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ABOGEN INC
Developers of antibodies, novel vaccines and cell and gene therapies are all slated to get funding support as Shanghai unleashes a flurry of incentives and policies to lead China’s push to become a global biopharma powerhouse.
Originated by a Suzhou-based biotech founded two years ago and now being jointly developed with WalVax, China’s first homegrown mRNA COVID-19 vaccine is now entering the final stages of development.
As the US responds to calls to waive intellectual property rights related to COVID-19 vaccines, China is already moving ahead with some of its own mRNA candidates.